Journals / Retina-Vitreus / 2009 / Cilt: 17 - Sayı: 4

Prognostic factors for final visual acuity and recurrence in active ocular toxoplasmosis

Aktif oküler toksoplazmoziste nüks ve sonuç görme keskinliğini etkileyen prognostik faktörler

Pages
255–262
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Recurrence risk is influenced by duration of infection and increasing during the follow-up.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To present ocular features, visual outcome, and efficacy of treatment in patients with ocular toxoplasmosis (OT), and to identify risk factors for visual loss and recurrence.
📊
Key Findings & Data:Materials and Methods: Ocular findings of 60 eyes (60 patients) with active OT followed at Uvea-Behcet Section in Ulucanlar Eye Education and Research Hospital between 1995-2009 were reviewed retrospectively.
💡
Conclusion & Impact:Recurrence risk is influenced by duration of infection and increasing during the follow-up.
🔬Design:Review & Systematic Survey
📍Scope:2009 Verileri
⚙️Variables:Seyir · Tekrarlama · Geriyedönük çalışma

Abstract

Purpose: To present ocular features, visual outcome, and efficacy of treatment in patients with ocular toxoplasmosis (OT), and to identify risk factors for visual loss and recurrence. Materials and Methods: Ocular findings of 60 eyes (60 patients) with active OT followed at Uvea-Behcet Section in Ulucanlar Eye Education and Research Hospital between 1995-2009 were reviewed retrospectively. Results: The mean follow-up was 27.9 (1-88) months. In 19 patients (31.7%) active lesion was accompanied with typical scar of toxoplasmosis. The most frequent complication was epiretinal membrane (13.3%). Nine different antiparasitic treatments were used in 54 (90%) 54 (90%) patients. Systemic steroids were added in 39 (65%) patients. The treatment had no effect on visual outcome and recurrences (p=0.01). The recurrence was observed in 13 patients (21.7%). Significant relation was found between the recurrence and duration of infection. Moreover, as age of patients and number of scar were increased, and initial visual acuity was decreased, final visual acuity was also decreased. Legal blindness was present in 8 patients (13.3%) in whom the most common cause was macular involvement. Kaplan-Meier survival analysis estimated cumulative risk of recurrence as 54% at 68 months of follow-up. Conclusion: Although prognosis of OT is commonly satisfactory, it can affect macula and impairs visual acuity. Initial visual acuity, age, and number of scar are detected as risk factors for visual prognosis. Recurrence risk is influenced by duration of infection and increasing during the follow-up.

Özet

Amaç: Oküler toksoplazmozisli (OT) hastaların klinik özelliklerini, görme prognozunu, tedavinin etkinliğini tanımlamak, görme kaybı ve nüks riski altında olan hastaların profilini saptamak. Gereç ve Yöntem: 1995-2009 tarihleri arasında Ulucanlar Göz Eğitim ve Araştırma Hastanesi, Üvea ve Behçet Birimi’nde izlenen 60 aktif OT’li hastaya ait 60 gözün oküler bulguları retrospektif olarak incelendi. Bulgular: Ortalama izlem süresi 27.9 (1-88) aydı. On dokuz hastada (%31.7) aktif lezyonun olduğu gözde tipik toksoplazmozis skarı vardı. En sık rastlanan komplikasyon epiretinal membran (%13.3) idi. Elli dört hastaya (%90) 9 farklı antiparazitik tedavi uygulandı. Otuz dokuz hastaya (%65) sistemik steroid de eklendi. Tedavinin görme keskinliği ve nüks gelişimine etkisi saptanmadı. Nüks 13 hastada (%21.7) saptandı. Aktif hastalık süresi ile nüks arasında anlamlı bir ilişki bulundu (p=0.01). Ayrıca, yaş arttıkça, ilk görme keskinliği azaldıkça, skar sayısı arttıkça son görme keskinliği azalmaktaydı. Legal körlük 8 hastada (%13.3) izlendi, en sık sebep makuler tutulumdu. Kaplan-Meier survival analizine göre 68. ayda nüks oluşumunun kümülatif olasılığı %54 idi. Tartışma: Oküler toksoplazmozisin prognozu genellikle memnun edici olsa da, makulayı etkileyebilir ve görmeyi bozabilir. Görme prognozu için ilk görme keskinliği, yaş ve skar sayısı “risk faktörü” olarak saptanmıştır. Nüks riski hastalık süresinden etkilenmektedir ve izlem süresince artmaktadır.

🔖

Cite This Article

YILMAZ, M. B., ÖZDAL, M. P. Ç., ÖZDEMİR, P., KAVUNCU, S., ÖZTÜRK, F. (2009). Prognostic factors for final visual acuity and recurrence in active ocular toxoplasmosis. Retina-Vitreus, Cilt: 17 - Sayı: 4, 255–262. https://ajindex.com/articles/307754

References (19)

  1. Jones JL, Kruszon-Moran D, Wilson M, et al.: Toxoplasma gondii infection in the United States: seroprevalence and risk factors. Am J Epidemiol. 2001;154:357-365
  2. Holland GN.: Ocular toxoplasmosis: a global reassessment. Part I: epidemiology and course of disease. Am J Ophthalmol. 2003; 136:973-988
  3. Scherrer J, Iliev ME, Halberstadt M, et al.: Visual function in human ocular toxoplasmosis. Br J Ophthalmol. 2006;91:233-236
  4. Bosch-Driessen LE, Berendschot TT, Ongkosuwito JV, et al.: Ocular toxoplasmosis: clinical features and prognosis of 154 patients. Ophthalmology. 2002;109:869-878
  5. Nussenblatt NB, Whitcup SM, Palestine AG.: Uveitis: fundamentals and clinical practice, Vol
  6. St Louis: Mosby, 1996
  7. Holland GN, O’Connor GR, Belfort R Jr, et al.: Toxoplasmosis. In: Pepose JS, Holland GN, Wilhelmus KR, eds. Ocular Infection and Immunity. St. Louis, MO: Mosby. 1996;1183-223
  8. Holladay JT.: Visual acuity measurements. J Cataract Refract Surg. 2004;30:287-290
  9. Friedmann CT, Knox DL.: Variations in recurrent active toxoplasmic retinochoroiditis. Arch Ophthalmol. 1969;81:481-493
  10. Gilbert RE, Dunn DT, Lightman S, et al.: Incidence of symptomatic toxoplasma eye disease: aetiology and public health implications. Epidemiol Infect. 1999;123:283-289
  11. Glasner PD, Silveira C, Kruzson-Moran D, et al.: An unusually high prevalence of ocular toxoplasmosis in southern Brazil. Am J Ophthalmol. 1992;114:136-144
  12. Delair E, Monnet D, Grabar S, et al.: Respective roles of acquired and congenital infections in presumed ocular toxoplasmosis. Am J Ophthalmol. 2008;146:851-855
  13. Atmaca LS, Simsek T, Batioglu F.: Clinical features and prognosis in ocular toxoplasmosis. Jpn J Ophthalmol. 2004;48:386-391
  14. Rothova A.: Ocular involvement in toxoplasmosis. Br J Ophthalmol. 1993;77:371-377
  15. Tugal-Tutkun I, Corum I, Otük B, et al. Active ocular toxoplasmosis in Turkish patients: a report on 109 cases. Int Ophthalmol. 2005;26:221-228
  16. Koppe JG, Loewer-Sieger DH, de Roever-Bonnet H.: Results of 20-year follow-up of congenital toxoplasmosis. Lancet. 1986;1: 254-256
  17. Burnett AJ, Shortt SG, Isaac-Renton J, et al.: Multiple cases of acquired toxoplasmosis retinitis presenting in an outbreak. Ophthalmology. 1998;105:1032-1037
  18. Westfall AC, Lauer AK, Suhler EB, et al.: Toxoplasmosis retinochoroiditis and elevated intraocular pressure: a retrospective study. J Glaucoma. 2005;14:3-10
  19. Folk JC, Lobes LA.: Presumed toxoplasmic papillitis. Ophth